NEW YORK (GenomeWeb News) – Newly minted public company Cancer Genetics has disclosed that it will invest at least $2.0 million, and potentially up to $6.0 million, into a joint venture the firm formed in November 2011 with the Mayo Foundation for Medical Education and Research.

The Rutherford, NJ-based cancer molecular diagnostics company disclosed more details about the joint venture in its Form 10-Q, filed this week with the US Securities and Exchange Commission. The JV is focused on the development of oncology diagnostics based on next-generation sequencing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.